Achromatopsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Achromatopsia is a rare autosomal recessive retinal disorder that leads to color blindness, nystagmus, photophobia, and severely reduced visual acuity due to cone function impairment or absence. It is characterized by reduced visual acuity, pendular nystagmus, photophobia, a small central scotoma, and reduced or complete loss of color discrimination. Most individuals with ACHM exhibit complete ACHM, where all three types of cones lack function, resulting in severe symptoms. In some rare cases, incomplete ACHM occurs, with milder symptoms due to the presence of functional cones. ACHM is associated with five genes: GNAT2, PDE6C, PDE6H, CNGA3, and CNGB3, all critical components of the cone phototransduction cascade. CNGB3 mutations are the most common, followed by CNGA3, while others are rare causes of ACHM. Achromatopsia comes in two types: complete, with no functional cones, and incomplete, with some functional cones. The differential diagnosis includes conditions like blue cone monochromatism, Leber congenital amaurosis, other cone dystrophies, and cerebral achromatopsia.

·       Unfortunately, there is currently no cure for achromatopsia, affecting about one in 30,000 live births.

 

Thelansis’s “Achromatopsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achromatopsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Achromatopsia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Achromatopsia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Achromatopsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Achromatopsia, Achromatopsia market outlook, Achromatopsia competitive landscape, Achromatopsia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)